The Centre addresses current priorities in inflammatory disease in an open innovation, pre-competitive collaboration between academia and the pharmaceutical
industry. GlaxoSmithKline, AstraZeneca and The University of Manchester have each invested £5M to promote “blue skies” research over the next 5 years. Our mission is to bring together clinical, industrial, and academic scientists – and innovate at this interface or in this unique interactive environment.
As part of our enabling strategy, the Centre has invested in unique, state-of-the-art facilities.
+/- Flow Cytometry Suite
+/- Ex Vivo Modelling
+/- In Vivo Modelling